$130.86▾ 0.68%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.17cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
10th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
+4.4%year over year
Watch
Revenue growth has flattened.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Gilead Sciences, Inc. turns 117¢ of every reported profit-dollar into real cash. Revenue growth has flattened. Its valuation sits in the cheaper end of its own recent range. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$7.34
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin31.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$29.74B
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days10 articles
2 bullish8 neutral0 bearish
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees- iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.